XML 34 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
10. Stock-Based Compensation

Equity Incentive Plans

In May 2017, our Board of Directors adopted, and our stockholders approved, the 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan provides for the grant of incentive stock options to employees and for the grant of nonstatutory stock options, restricted stock awards, restricted stock units (“RSUs”), stock appreciation rights, performance-based stock awards, and other forms of equity compensation to employees, including officers, non-employee directors, and consultants. We initially reserved 6,421,442 shares of Class A common stock for issuance under the 2017 Plan, which included 421,442 shares that remained available for issuance under our 2007 Stock Option Plan (the “2007 Plan”) at the time the 2017 Plan became effective. The number of shares reserved under the 2017 Plan increases for any shares subject to outstanding awards originally granted under the 2007 Plan that expire or are forfeited prior to exercise. As a result of the adoption of the 2017 Plan, no further grants may be made under the 2007 Plan. As of December 31, 2024, there were 7,196,533 shares of Class A common stock reserved for issuance under the 2017 Plan, of which 2,009,200 are still available to be issued.
Stock Options

In June 2022, our Board of Directors granted a stock option to purchase 700,000 shares of our Class A common stock to our Chief Executive Officer (the “2022 CEO Grant”) under the 2017 Plan with an exercise price of $50.63 per share. The 2022 CEO Grant is eligible to vest based on the achievement of various stock price appreciation targets of our Class A common stock. Specifically, the 2022 CEO Grant vests in four installments of 25% each if the average closing price per share for a 365 day calendar period equals or exceeds each of $175, $200, $225, and $250, respectively (the “Vesting Price Threshold”), prior to June 7, 2030. The option also vests if the Company engages in a Corporate Transaction, as defined in the Plan, in which the Company’s Class A common stock is valued at or above the Vesting Price Threshold. The fair value of the 2022 CEO Grant was determined using a Monte Carlo simulation. The fair value of the award at the grant date was $18.8 million and is being amortized over derived service periods ranging from 3.4 years to 4.1 years.

The only stock option awarded during the years ended December 31, 2024, 2023, and 2022 was the 2022 CEO Grant. The following table summarizes the assumptions used to estimate the fair value of the 2022 CEO stock option grant:

Year Ended December 31,
202420232022
Risk-free interest rate**3.01%
Expected term (in years)****
Expected volatility**70.00%
Expected dividend yield**—%
* Not applicable because no stock options were granted during the period.
** Each Vesting Price Threshold for the 2022 CEO grant has a unique expected term ranging from 3.4 years to 4.1 years.
The following table summarizes stock option activity for the years ended December 31, 2024, 2023, and 2022:

Number of SharesWeighted Average Exercise Price
Weighted Average Remaining Contractual Term (in years)
Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2021
2,953,356 $15.16 4.0$147,812 
Granted700,000 50.63 
Exercised(937,217)27.14 32,858 
Expired(7,900)4.06 
Forfeited(10,280)12.28 
Outstanding at December 31, 2022
2,697,959 20.25 5.145,862 
Granted— — 
Exercised(98,610)7.56 3,387 
Expired— — 
Forfeited— — 
Outstanding at December 31, 2023
2,599,349 20.73 4.253,089 
Granted— — 
Exercised(1,543,436)9.37 36,383 
Expired(384)12.00 
Forfeited— — 
Outstanding at December 31, 2024
1,055,529 $37.34 5.6$7,751 
Exercisable at December 31, 2024
355,529 $11.18 2.1$7,751 

No stock options were vested during the year ended December 31, 2024 and 2023. The total fair value of stock options that vested during the year ended December 31, 2022 was $0.9 million. As of December 31, 2024, the total compensation cost related to unvested stock options not yet recognized, which relates exclusively to the 2022 CEO Grant, was $5.9 million. This amount will be recognized over a remaining weighted average period of 1.22 years.
Restricted Stock Units

The following table summarizes RSU activity for the years ended December 31, 2024, 2023, and 2022:

Number of SharesWeighted Average Grant Date Fair Value
Non-vested and outstanding at December 31, 2021
1,209,529 $70.99 
Granted606,203 52.63 
Vested(403,648)58.63 
Forfeited(221,364)70.30 
Non-vested and outstanding at December 31, 2022
1,190,720 65.97 
Granted710,278 42.52 
Vested(668,119)58.64 
Forfeited(154,815)62.73 
Non-vested and outstanding at December 31, 2023
1,078,064 55.52 
Granted987,528 35.61 
Vested(657,897)52.04 
Forfeited(261,535)45.81 
Non-vested and outstanding at December 31, 2024
1,146,160 $42.59 

As of December 31, 2024, total unrecognized compensation cost related to unvested RSUs was approximately $32.1 million, which will be recognized over a weighted average period of 1.5 years.

The following table summarizes the components of our stock-based compensation expense by instrument type for the years ended December 31, 2024, 2023, and 2022 (in thousands):

Year Ended December 31,
202420232022
RSUs$33,267 $37,563 $35,290 
Stock options5,059 5,045 2,790 
Common stock awards to Board of Directors719 779 750 
Total stock-based compensation expense$39,045 $43,387 $38,830 

The following table summarizes stock-based compensation expense by line item in the accompanying consolidated statements of operations for the years ended December 31, 2024, 2023, and 2022 (in thousands):

Year Ended December 31,
202420232022
Cost of revenue
Subscriptions$848 $925 $996 
Professional services5,674 6,055 5,309 
Operating expenses
Sales and marketing8,200 10,842 9,152 
Research and development11,716 12,486 12,523 
General and administrative12,607 13,079 10,850 
Total stock-based compensation expense$39,045 $43,387 $38,830